X4 Pharmaceuticals (XFOR) News Today → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free XFOR Stock Alerts $1.01 -0.01 (-0.98%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 7 at 6:55 PM | marketbeat.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Acquired by Bain Capital Life Sciences Investors LLCBain Capital Life Sciences Investors LLC increased its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) by 6.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 16,915,784 shares of thJune 3, 2024 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 1, 2024 | americanbankingnews.comX4 Pharmaceuticals (NASDAQ:XFOR) Receives Overweight Rating from Cantor FitzgeraldMay 31, 2024 | marketbeat.comCantor Fitzgerald Reiterates "Overweight" Rating for X4 Pharmaceuticals (NASDAQ:XFOR)Cantor Fitzgerald restated an "overweight" rating and set a $5.00 target price on shares of X4 Pharmaceuticals in a research note on Friday.May 29, 2024 | globenewswire.comX4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic NeutropeniaMay 13, 2024 | globenewswire.comX4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceMay 10, 2024 | marketbeat.comBrokers Set Expectations for X4 Pharmaceuticals, Inc.'s FY2028 Earnings (NASDAQ:XFOR)X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - HC Wainwright lifted their FY2028 earnings per share (EPS) estimates for X4 Pharmaceuticals in a research report issued on Wednesday, May 8th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.May 9, 2024 | globenewswire.comX4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan FacilityMay 8, 2024 | markets.businessinsider.comOptimistic Buy Rating for X4 Pharmaceuticals Following FDA Approval and Strong Clinical ProspectsMay 8, 2024 | finance.yahoo.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call TranscriptMay 8, 2024 | finance.yahoo.comX4 Pharmaceuticals Inc (XFOR) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...May 7, 2024 | seekingalpha.comX4 Pharmaceuticals GAAP EPS of -$0.26May 7, 2024 | investorplace.comXFOR Stock Earnings: X4 Pharmaceuticals Misses EPS for Q1 2024May 7, 2024 | sfgate.comX4 Pharmaceuticals: Q1 Earnings SnapshotMay 7, 2024 | globenewswire.comX4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesMay 2, 2024 | marketbeat.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Forecasted to Earn Q3 2024 Earnings of ($0.19) Per ShareX4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Brookline Capital Management dropped their Q3 2024 earnings per share estimates for shares of X4 Pharmaceuticals in a research report issued to clients and investors on Monday, April 29th. Brookline Capital Management analyst L. Cann now foreMay 1, 2024 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2024 | marketbeat.comBrookline Capital Management Equities Analysts Increase Earnings Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Equities research analysts at Brookline Capital Management increased their FY2026 earnings estimates for X4 Pharmaceuticals in a research report issued to clients and investors on Monday, April 29th. Brookline Capital Management analyst L. CaApril 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for X4 Pharmaceuticals’ Xolremdi on Robust Clinical Efficacy and Favorable Market StrategyApril 30, 2024 | finance.yahoo.comXFOR: XOLREMDI™ Approved by FDA…April 30, 2024 | marketbeat.comHC Wainwright Raises X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $5.00HC Wainwright upped their target price on X4 Pharmaceuticals from $3.00 to $5.00 and gave the stock a "buy" rating in a research report on Tuesday.April 30, 2024 | globenewswire.comX4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024April 29, 2024 | seekingalpha.comX4 Pharmaceuticals: FDA Approval For WHIM Warrants Further UpsideApril 29, 2024 | msn.comX4 gets FDA approval for Xolremdi for WHIM syndromeApril 29, 2024 | bizjournals.comX4 Pharmaceuticals’ bet on drug for ultra-rare disease pays off with FDA approvalApril 29, 2024 | marketbeat.comStock Traders Purchase Large Volume of Put Options on X4 Pharmaceuticals (NASDAQ:XFOR)X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Get Free Report) was the target of some unusual options trading on Monday. Stock traders purchased 2,515 put options on the stock. This represents an increase of 132% compared to the average daily volume of 1,084 put options.April 29, 2024 | marketwatch.comX4 Pharmaceuticals Gets FDA Approval for Xolremdi CapsulesApril 29, 2024 | finanznachrichten.deX4 Pharmaceuticals Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM SyndromeApril 29, 2024 | markets.businessinsider.comX4 Pharma's XOLREMDI Capsules Gets FDA Approval To Treat WHIM SyndromeApril 29, 2024 | finance.yahoo.comUPDATE 1-US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency diseaseApril 29, 2024 | reuters.comUS FDA approves X4 Pharmaceuticals' drug for immunodeficiency diseaseApril 29, 2024 | globenewswire.comX4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM SyndromeApril 18, 2024 | seekingalpha.comX4 Pharmaceuticals: PDUFA Excitement AheadApril 17, 2024 | msn.comX4 Pharmaceuticals (XFOR) Price Target Increased by 8.75% to 3.62April 11, 2024 | finance.yahoo.comX4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returnsApril 5, 2024 | marketbeat.comResearch Analysts Issue Forecasts for X4 Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:XFOR)X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Analysts at Zacks Small Cap issued their Q1 2024 earnings estimates for shares of X4 Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 2nd. Zacks Small Cap analyst D. Bautz forecasts that the company willApril 4, 2024 | marketbeat.comBrokers Set Expectations for X4 Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:XFOR)X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Analysts at Zacks Small Cap issued their Q2 2024 earnings per share (EPS) estimates for X4 Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 2nd. Zacks Small Cap analyst D. Bautz forecasts that the companyApril 2, 2024 | globenewswire.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 2, 2024 | finance.yahoo.comXFOR: PDUFA Date of April 30, 2024 for Mavorixafor for WHIM Syndrome…April 1, 2024 | globenewswire.comX4 Pharmaceuticals to Participate in Upcoming April Investor ConferencesMarch 23, 2024 | seekingalpha.comX4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | markets.businessinsider.comBuy Rating Affirmed on X4 Pharmaceuticals Amid Positive Mavorixafor ProspectsMarch 22, 2024 | marketbeat.comX4 Pharmaceuticals (NASDAQ:XFOR) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $3.00 price target on shares of X4 Pharmaceuticals in a research report on Friday.March 22, 2024 | insidermonkey.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2023 Earnings Call TranscriptMarch 22, 2024 | finance.yahoo.comQ4 2023 X4 Pharmaceuticals Inc Earnings CallMarch 21, 2024 | investorplace.comXFOR Stock Earnings: X4 Pharmaceuticals Beats EPS for Q4 2023March 21, 2024 | finance.yahoo.comX4 Pharmaceuticals Inc (XFOR) Reports Fourth-Quarter and Full-Year 2023 Financial ResultsMarch 21, 2024 | globenewswire.comX4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | marketbeat.comPolar Capital Holdings Plc Sells 2,500,000 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)Polar Capital Holdings Plc decreased its holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) by 25.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,500,000 shares of the company's stock after sMarch 12, 2024 | globenewswire.comX4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024 Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (Ad)Optimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight! TRY "INVESTING IDEAS" TODAY XFOR Media Mentions By Week XFOR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XFOR News Sentiment▼0.900.76▲Average Medical News Sentiment XFOR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XFOR Articles This Week▼22▲XFOR Articles Average Week Get X4 Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CDTX News Today RGNX News Today EXAI News Today TSHA News Today HLVX News Today VALN News Today ITOS News Today LXEO News Today KYTX News Today ADPT News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XFOR) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored